Introduction and Summary of the Workshop “Drug Research Support: SelectioN and Early Development”

Toxicologic Pathology

Volumn 30, Issue 1, 2002, Pages 2-3

  Tryphonas, Leander ^a   Germann, Paul Georg ^b  

^a Consultants in Pathology and Toxicology ^*  (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DRUG RESEARCH; MEDICAL EDUCATION; MEDICAL PRACTICE; PATHOLOGY; PRIORITY JOURNAL;

PATHOLOGY; PHARMACOLOGY; RESEARCH SUPPORT;

EID: 0036192159     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230252824635     Document Type: Article

References (9)

1. Burkhardt JE, Floyd E., Kerlin RL, Adler RR, Ochoa R., Reynolds JA (1999). A view on discovery pathology. Toxicol Pathol 27: 472-473.
2. Car BD, Robertson RT (1999). Discovery toxicology—A nascent science. Toxicol Pathol 27: 481-483.
3. Cockerell GL, Burkhardt JE, Ryan AM (1999). Focus on: Discovery pathology. Toxicol Pathol 27: 471.
4. Cockerell GL, Aaron CS, Moe JB (1999). Redesigning the preclinical paradigm: The role of pathology and toxicology in supporting discovery research. Toxicol Pathol 27: 477-478.
5. Germann PG, Häfner D., Hanauer G., Drommer W. (1998). J Exp Anim Sci 39: 22-33.
6. Harleman JH (1999). Contribution of pathology to drug research and development in the next decade. Toxicol Pathol 27: 479-480.
7. Ryan AM (1999). Role of the pathologist in the identification and characterization of therapeutic molecules. Toxicol Pathol 27: 474-476.
8. Schwetz BA (2000). Toxicology at the food and drug administration. Int Toxicol 20: 3-8.
9. STP Homepage (11.10.2000). Investigative Toxicology and Pathology Interest Group. www.toxpath.org/Intra.htm